Precision Diagnostics in Inflammatory Bowel Disease, Cellular Therapy and Transplantation (The PREDICT Trial)
At a glance
Conditions
NCT03369353
Where you'd take part
This study runs at 4 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Boston Children's Hospital
Boston, Massachusettsno site contact published
Dana-Farber Cancer Institute
Boston, Massachusettsno site contact published
Massachusetts General Hospital
Boston, Massachusettsno site contact published
Seattle Children's Hospital
Seattle, Washingtonno site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Leslie Kean, MD, PhD · PRINCIPAL_INVESTIGATOR · Boston Children's Hospital
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Perform flow cytometry, TCR deep sequencing and whole transcriptome analysis on T cells purified from GI endoscopy samples taken for presumed GI GVHD, inflammatory bowel disease (IBD), and functional gastrointestinal disease (FGID).1 year
To identify the mechanisms specific for auto-immune and allo-immune GI disorders.
- Perform flow cytometry, TCR deep sequencing and transcriptome analysis on T cells from the peripheral blood in patients diagnosed with GI GVHD, IBD and FGID and patients receiving cellular therapies.1 year
To identify the mechanisms specific for allo- and auto-immune diseases and the consequences of cellular therapy delivery.